These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27491145)

  • 21. Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial.
    Fogari R; Mugellini A; Destro M; Corradi L; Lazzari P; Zoppi A; Preti P; Derosa G
    Diabet Med; 2012 Jan; 29(1):24-31. PubMed ID: 21781149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A decrease in left ventricular hypertrophy and the dynamics of the parameters of circadian BP monitoring under the influence of ramipril in patients with essential arterial hypertension].
    Pekarskiĭ SE; Vorozhtsova IN; Mordovin VF
    Ter Arkh; 1997; 69(4):18-20. PubMed ID: 9213948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of changes in blood pressure and left ventricular mass induced by antihypertensive treatment on ventricular arrhythmias in essential hypertension.
    Muiesan ML; Zulli R; Rizzoni D; Calebich S; Malerba M; Porteri E; Agabiti-Rosei E
    J Hypertens Suppl; 1993 Dec; 11(5):S104-5. PubMed ID: 8158296
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
    J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
    Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
    Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Lindholm LH; Dahlöf B;
    Hypertension; 2007 Nov; 50(5):984-90. PubMed ID: 17893425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of overweight and obesity on cardiac benefit of antihypertensive treatment.
    Gerdts E; de Simone G; Lund BP; Okin PM; Wachtell K; Boman K; Nieminen MS; Dahlöf B; Devereux RB
    Nutr Metab Cardiovasc Dis; 2013 Feb; 23(2):122-9. PubMed ID: 21775111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension.
    Pouleur AC; Uno H; Prescott MF; Desai A; Appelbaum E; Lukashevich V; Smith BA; Dahlöf B; Solomon SD;
    J Renin Angiotensin Aldosterone Syst; 2011 Dec; 12(4):483-90. PubMed ID: 21746765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The effectiveness and tolerability of losartan and effect on left ventricular mass in patients with essential hypertension].
    Tedesco MA; Ratti G; Aquino D; Caccavale A; Acitorio M; Rocereto A; Cosimi R; Coppolino P; Iarussi D; Iacono A
    Cardiologia; 1998 Jan; 43(1):53-9. PubMed ID: 9534293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients.
    Okin PM; Hille DA; Larstorp AC; Wachtell K; Kjeldsen SE; Dahlöf B; Devereux RB
    Hypertension; 2015 Aug; 66(2):368-73. PubMed ID: 26056336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention For Endpoint reduction.
    Olsen MH; Wachtell K; Borch-Johnsen K; Okin PM; Kjeldsen SE; Dahlöf B; Devereux RB; Ibsen H
    J Hum Hypertens; 2002 Aug; 16(8):591-5. PubMed ID: 12149666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease.
    Shibasaki Y; Masaki H; Nishiue T; Nishikawa M; Matsubara H; Iwasaka T
    Nephron; 2002 Mar; 90(3):256-61. PubMed ID: 11867945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication.
    Yoshida C; Goda A; Naito Y; Nakaboh A; Matsumoto M; Otsuka M; Ohyanagi M; Hirotani S; Lee-Kawabata M; Tsujino T; Masuyama T
    J Hypertens; 2011 Feb; 29(2):357-63. PubMed ID: 21052021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
    Søraas CL; Wachtell K; Okin PM; Dahlöf B; Devereux RB; Tønnessen T; Kjeldsen SE; Olsen MH
    Blood Press; 2010 Jun; 19(3):145-51. PubMed ID: 20429689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypertension, inflammation and atrial fibrillation.
    Angeli F; Reboldi G; Verdecchia P
    J Hypertens; 2014 Mar; 32(3):480-3. PubMed ID: 24477094
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial.
    Amador N; Encarnación JJ; Guízar JM; Rodríguez L; López M
    J Hum Hypertens; 2005 Apr; 19(4):277-83. PubMed ID: 15674406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
    Olsen MH; Wachtell K; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Lyle PA; Nieminen MS
    J Hum Hypertens; 2006 Jun; 20(6):460-4. PubMed ID: 16572193
    [No Abstract]   [Full Text] [Related]  

  • 40. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
    Kizer JR; Dahlöf B; Kjeldsen SE; Julius S; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Wachtell K; Edelman JM; Snapinn SM; Harris KE; Devereux RB
    Hypertension; 2005 Jan; 45(1):46-52. PubMed ID: 15583076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.